跳至主要内容
临床试验/CTIS2024-515408-37-00
CTIS2024-515408-37-00进行中(未招募)1 期

MRI with hyperpolarized pyruvate in gliblastoma - a phase II study

Aarhus Universitet0 个研究点目标入组 10 人开始时间: 2024年6月19日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • Patients with newly diagnosed high-grade glioma (grade 3 and 4), Scheduled for radiotherapy, At least 18 years of age, WHO performance status 0-2, Women who are not postmenopausal or surgically sterile must have a negative serum or urine pregnancy test performed at time of inclusion in the study. Safe and highly effective contraception must be used throughout the study meaning either hormonal anti-conception or an anti-fertility intrauterine device. If the partner is non fertile or the patient has no sexual activities, this is also accepted., Danish speaking, Able and willing to comply after informed consent

排除标准

  • History of alcohol abuse or illicit drug use., Allergy to pyruvate, Contraindications to MRI o Pacemaker, neurostimulator or cochlea implant o Metal foreign bodies such as fragments and irremovable piercings o Unsafe medical implants (safety of heart valves, hips and the like must be confirmed) o Intracranial clips or coils o Claustrophobia o Largest circumference including arms > 160 cm, Contraindications to gadolinium contrast o eGFR = 30 mL/min/1.73m2 o Previous adverse reactions to gadolinium, Not able or willing to receive radiotherapy, Predicted remaining survival <3 months, Symptomatic cardiac disease (i.e. valve disease, coronary artery disease, arrythmias etc.). Hypertension and hyperlipidemia are allowed., Subjects who are receiving any other investigational agents., Previous or current treatment by radiation or chemotherapy.

研究者

相似试验

MRI with hyperpolarized pyruvate in gliblastoma - a... | 临床试验